Drug Topics
AUGUST 9, 2024
A cohort study was conducted to address the association between patients with cannabis-related disorders and their risk of developing head and neck cancer.
PharmaVoice
AUGUST 9, 2024
Here’s what the leaders of the companies with the 10 drugs in the first wave of price negotiations with Medicare said about how the new prices will impact their portfolio.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
AUGUST 9, 2024
The composition of the latest flu vaccine has changed. Here’s what pharmacists need to know.
Pharmacy Times
AUGUST 9, 2024
neffy is an epinephrine nasal spray for the emergency treatment of allergic reactions in adults and pediatric patients.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
AUGUST 9, 2024
Findings from the study conducted by 3 Axis Advisors confirm that PBM practices have an impact on pharmacies.
STAT
AUGUST 9, 2024
Noah Lyles, a 27-year-old from Gainesville, Florida, has had himself quite an Olympics. He won a gold medal in a photo finish in the 100-meter dash on August 4. He went on to win a bronze medal in the 200-meter dash four days later, then collapsed in a heap and needed a wheelchair to get off the track, suggesting that sports officials and team doctors have put athletes’ health last, not first, during the Paris Olympics.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
AUGUST 9, 2024
The Centers for Disease Control and Prevention issued a new risk assessment of the H5N1 bird flu virus circulating in dairy cows on Friday, increasing slightly its estimate of the chance it poses of triggering a pandemic. The new assessment , developed using the CDC’s influenza risk assessment tool or IRAT, gauged the risk the virus might someday cause a pandemic at 5.79, up from a previous score of 5.12 from an assessment of a related virus conducted in April 2023.
Drug Topics
AUGUST 9, 2024
The epinephrine nasal spray from ARS Pharmaceuticals has become the first and only needle-free epinephrine alternative and the first new delivery method for epinephrine in over 3 decades.
STAT
AUGUST 9, 2024
On Friday, the Food and Drug Administration approved the first needle-free treatment for adults and kids with severe allergic reactions. The approval introduces a competitor from ARS Pharma to older epinephrine products, like the EpiPen. Neffy, as the product is called, is a nasal spray that delivers the same drug used to treat anaphylaxis. It is ARS’ flagship product.
Drug Topics
AUGUST 9, 2024
Check out important updates from the FDA for the week of August 5.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
AUGUST 9, 2024
The Food and Drug Administration rejected MDMA as a treatment for post-traumatic stress disorder on Friday, in a blow to drug activists and veterans who’ve long campaigned for the psychedelic treatment. Although two Phase 3 trials suggested the treatment was effective, strong opposition by an agency scientific advisory committee in June and allegations of missing adverse event data and research bias may have doomed the application by Lykos Therapeutics.
Drug Topics
AUGUST 9, 2024
See what’s trending in pharmacy with a preview of the Drug Topics July/August issue.
Pharmacy Times
AUGUST 9, 2024
Statins and non-statin cholesterol-lowering agents show potential in reducing the risk of liver cancer.
STAT
AUGUST 9, 2024
Will it work? It was the question everyone around Susannah Rosen kept asking. Since infancy, she’d lived with a rare neurologic disease. She’d struggled to walk and talk, only to have the degenerative disease mostly rob her of those skills. Hardly a day passed without her suffering seizures, leaving her in need of constant care. But in October 2022, Susannah’s family had reason to be hopeful.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
AUGUST 9, 2024
Pharmacy is at a fork in the road.
STAT
AUGUST 9, 2024
The American medical system needs fiction because, as Albert Camus supposedly said , “Fiction is the lie through which we tell the truth.” And those in health care, from hospital administrators to clinicians and technicians, need to hear the real truth about health care. For decades, a small group of physician and nurse writers has provided behind-the-scenes looks at the experiences of being a doctor, the lives saved, the ones lost, and how the profession has changed the way many p
Pharmacy Times
AUGUST 9, 2024
Previously, an independent advisory panel for the FDA rejected the use of MDMA-assisted therapy for posttraumatic stress disorder (PTSD), citing concerns of the reliability of the clinical trial data.
STAT
AUGUST 9, 2024
A decades-long campaign to legalize MDMA as a mainstream medical treatment will reach a climax as soon as Friday, with the Food and Drug Administration poised to decide whether the psychedelic should be approved as a treatment for post-traumatic stress disorder in conjunction with psychotherapy. The regulators face an Aug. 11 deadline to decide whether to sign off on the drug or reject it.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
AUGUST 9, 2024
A variety of signs and symptoms of lymphoma were reported, including fever, stomach discomfort, and weight loss.
Fierce Healthcare
AUGUST 9, 2024
Drugstore chain Walgreens is considering a full sale of its stake in VillageMD after investing billions in the primary care provider. | Walgreens said its exploring options including a sale of all or part of the VillageMD businesses, possible restructuring options and other strategic opportunities, according to a recent filing.
Pharmacy Times
AUGUST 9, 2024
The study is expected to include 460 individuals that will be randomly treated with 12mg of ifinatamab deruxtecan or chemotherapy chosen by the health care provider.
pharmaphorum
AUGUST 9, 2024
Eli Lilly's oral tau drug fails to show efficacy in a phase 2 trial in Alzheimer's disease in another setback for the class
STAT
AUGUST 9, 2024
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in your inbox. I’m working on a playlist for an upcoming road trip. Got song suggestions for driving across vast landscapes? Email me: brittany.trang@statnews.
Pharmacy Times
AUGUST 9, 2024
The findings may lead to the development of diagnostic and therapeutic targets to prevent worsening disease in patients.
Fierce Healthcare
AUGUST 9, 2024
Medicare Advantage and Medicaid woes continued to plague some major payers in the second quarter, with UnitedHealth Group regaining its crown as the most profitable company in the industry for Q2.< | Medicare Advantage and Medicaid woes continued to plague some major payers in the second quarter, with UnitedHealth Group regaining its crown as the most profitable company in the industry for Q2.
pharmaphorum
AUGUST 9, 2024
Eli Lilly raises guidance for 2024 by $3 billion on strong growth for tirzepatide in diabetes and obesity and improved supply capacity
STAT
AUGUST 9, 2024
I usually do my grocery shopping at the end of the day when I am tired, stressed, and hungry. In a word, I am vulnerable. The sugary beverages, candy, baked goods, and salty snacks located at the front entrance, aisle end caps, and checkout lanes can be hard to resist. The food industry knows this about me — and you. But small changes in the “choice architecture” can help people avoid these unplanned impulse purchases and choose healthy foods.
Pharmacy Times
AUGUST 9, 2024
Dan Schrum discusses the integral role of pharmacy specialists in translating clinical trial results to clinical practice.
pharmaphorum
AUGUST 9, 2024
At the second attempt, the FDA has approved Citius Pharmaceuticals' Lymphir for rare lymphoma CTCL
Fierce Pharma
AUGUST 9, 2024
As Purdue Pharma attempts to restore its image following its role in | As Purdue Pharma attempts to restore its image following its role in the U.S. opioid crisis, the Connecticut-based company has scored a win with a green light for a new overdose rescue treatment.
pharmaphorum
AUGUST 9, 2024
Compliant chat ensures that Healthcare Professionals (HCPs) receive accurate information in a timely manner, fostering more meaningful relationships. Learn how to navigate compliance in your interactions with HCPs.
Fierce Pharma
AUGUST 9, 2024
With Gilead's stated focus to grow in oncology, the company's recent quarterly updates have placed a heavy emphasis on its developments in the cancer space. | The HIV-focused drugmaker looks to position its long-acting Sunlenca as a prime PrEP option after the med aced a phase 3 study.
STAT
AUGUST 9, 2024
Hey, humans. Today, we talk about the decades-long pursuit to get MDMA approved as a medicine for PTSD, in advance of Lykos Therapeutics’ Sunday PDUFA date. Also, we see a little girl’s ultra-rare disease improve after she was given a genetic medicine designed just for her, and more. The need-to-know this morning Merck acquired an experimental bispecific antibody from China-based Curon Biopharmaceutical for $700 million upfront, plus an additional $600 million in potential mileston
Expert insights. Personalized for you.
503 
Let's personalize your content